In a phase 3 clinical trial presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, the investigational oral drug daraxonrasib nearly doubled overall survival for patients with previously treated metastatic pancreatic cancer. The drug, which targets KRAS-driven signaling, reduced the risk of death by 60% compared to standard chemotherapy.
For decades, the KRAS gene has been considered one of the hardest targets in oncology. Found in more than 90% of pancreatic tumors, the gene produces proteins that act as a perpetual on switch for cell growth, yet its smooth molecular surface historically left it considered “undruggable.” That narrative shifted significantly on May 31, 2026, when researchers unveiled results from the RASolute 302 trial, a study of 500 patients.
Trial Outcomes and the Survival Benefit of Daraxonrasib
The study, led by investigators at the Dana-Farber Cancer Institute, randomized patients with previously treated metastatic pancreatic ductal adenocarcinoma to receive either daily oral daraxonrasib or standard chemotherapy. The results were stark: median overall survival reached 13.2 months for those on the new therapy, compared to just 6.7 months for the chemotherapy group.
Beyond overall survival, the trial met its secondary endpoints, including progression-free survival and objective response rates. Daraxonrasib also significantly delayed the deterioration of patient-reported pain and global quality of life. The drug works by binding to a molecule called cyclophilin A, which then attaches to the active RAS protein to effectively shut down its cancer-signaling capabilities. This mechanism allows it to target a range of RAS variants.
Safety Profile and Clinical Implementation
While the survival benefits are significant, the safety profile of daraxonrasib differs from the toxicity associated with traditional cytotoxic chemotherapy. The most frequent side effects reported in the study included skin rash and stomatitis—painful sores inside the mouth. Participants were less likely to discontinue treatment due to adverse events compared to those receiving chemotherapy.
The transition from intravenous chemotherapy to a daily oral pill represents a meaningful change in the patient experience. However, clinicians emphasize that the drug is not yet a cure.
Broadening the Scope: Zoldonrasib and Future Research
The success of daraxonrasib is part of a broader “RAS revolution” currently underway in gastrointestinal oncology. At the same 2026 conference, researchers presented early-phase data on another investigational therapy, zoldonrasib, which targets the specific KRAS G12D mutation. In a study of 81 patients, zoldonrasib was combined with standard first-line chemotherapy, showing high rates of tumor shrinkage and significant reductions in circulating tumor DNA.
“The emergence of therapies designed specifically against KRAS G12D represents one of the most promising areas of research in pancreatic cancer today. For many years, this mutation was considered impossible to target, making these early findings particularly important.”
These developments suggest that the field is moving toward a more personalized approach, where treatments are selected based on a patient’s specific genetic profile.
For now, the regulatory path forward for daraxonrasib remains the primary focus. With the data published in The New England Journal of Medicine, the manufacturer is expected to seek formal approval from the FDA and other global regulatory bodies. As the medical community assesses these results, the emphasis remains on confirming these benefits in real-world settings and determining how these targeted therapies might eventually be integrated into earlier stages of treatment, where they could potentially improve surgical outcomes.
Consult your healthcare provider to discuss whether clinical trials or emerging treatment options are appropriate for your specific diagnosis.
Worth a look
